Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune is set to resubmit its melanoma drug for FDA approval following a leadership change at the agency. The drug had previously faced two rejections under former Commissioner Marty Makary, who recently resigned. Replimune claims to have reached an agreement with the FDA, which will prioritize the review of their application.
- ▪Replimune plans to resubmit its melanoma drug to the FDA after a leadership shakeup.
- ▪The drug was previously rejected twice under former FDA Commissioner Marty Makary.
- ▪Replimune accused the FDA of wrongfully blocking their treatment, while the FDA cited issues with clinical trial guidance.
2 outlets in our directory ran this story, first to last over 1 hour. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/05/29/replimune-resubmit-melanoma-drug-fda-makary.html |
| Publication time | Fri, 29 May 2026 12:51:06 GMT |
| Retrieval time | 2026-05-29T13:00:00.516Z |
| Last seen | 2026-05-29T13:00:00.516Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | v_xjNodRmNaW · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Replimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at the agency, the company said Friday. The FDA twice rejected Replimune's melanoma treatment under the previous FDA leadership, including former Commissioner Marty Makary, who stepped down earlier this month. Replimune had accused the FDA of wrongfully blocking what some doctors see as a promising new way to treat the skin cancer, while the FDA had said Replimune ignored the agency's guidance for conducting its clinical trials.The bitter fight became a flashpoint for what some in the drug industry saw as mixed messaging from the FDA under Makary's leadership.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
